)
)
Galapagos Investor Relations Material
Latest events
Investor Update
Galapagos
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Galapagos NV
Access all reports
Segment Data
Access more data
Net revenue by
Source
Collaboration revenues
Product net sales
Expenses by
Financials
Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action. Our pipeline comprises four Phase 2 programs, three Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.
Key slides for Galapagos NV
Q2 2024
Galapagos NV
Q3 2024
Galapagos NV
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
GLPG
Country
🇳🇱 Netherlands